Results 121 to 130 of about 12,446 (175)
Mendelian susceptibility to mycobacterial disease: IFN-γ-driven immunity collapse underlies heterogeneous infections. [PDF]
Front ImmunolQian M +6 more
europepmc +1 more source
Recombinant Mycobacterium bovis BCG
Vaccine, 2009 The Bacillus Calmette-Guerin (BCG) is an attenuated strain of Mycobacterium bovis that has been broadly used as a vaccine against human tuberculosis. This live bacterial vaccine is able to establish a persistent infection and induces both cellular and humoral immune responses. The development of mycobacterial genetic systems to express foreign antigens
Sibele Borsuk +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Recombinant BCGs for tuberculosis and bladder cancer
Vaccine, 2021Bacillus Calmette-Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB ...
Alok K. Singh +3 more
openaire +2 more sources
Thirty years of recombinant BCG: new trends for a centenary vaccine
Expert Review of Vaccines, 2021 Introduction: Global perception of the potential for Bacille Calmette-Guérin (BCG), and consequently recombinant BCG (rBCG), in a variety of prophylactic and therapeutic applications has been increasing. A century of information on BCG, and three decades of experience with rBCG, has generated solid knowledge in this field. Area covered: Here, we review
Dunia Rodríguez +2 more
exaly +3 more sources
New use of BCG for recombinant vaccines [PDF]
Nature, 1991 BCG, a live attenuated tubercle bacillus, is the most widely used vaccine in the world and is also a useful vaccine vehicle for delivering protective antigens of multiple pathogens. Extrachromosomal and integrative expression vectors carrying the regulatory sequences for major BCG heat-shock proteins have been developed to allow expression of foreign ...
Graham Hatfull +2 more
exaly +3 more sources
Recombinant BCG Vaccine Candidates
Current Molecular Medicine, 2007Given the variable protective efficacy provided by Mycobacterium bovis BCG (Bacillus Calmette-Guérin), there is a concerted effort worldwide to develop better vaccines that could be used to reduce the burden of tuberculosis. Recombinant BCG (rBCG) are vaccine candidates that offer some potential in this area.
Rogelio, Hernàndez-Pando +3 more
openaire +2 more sources
Improved protection by recombinant BCG
Microbes and Infection, 2005Mycobacterium bovis bacille Calmette Guérin (BCG) is one of the most widely used live vaccines. Technologic advancement in genome manipulation enables the construction of recombinant BCG (rBCG) strains, which can be employed as highly immunogenic vaccines against tuberculosis with improved safety profile.
Nasser Eddine, A., Kaufmann, S.
openaire +3 more sources
Recombinant BCG as a candidate oral vaccine vector
Research in Microbiology, 1990Bacille Calmette-Guerin (BCG), currently the most widely used vaccine in the world, was originally administered for many years as an oral vaccine. The low frequency of serious complications, inexpensive production, and adjuvanticity make BCG an ideal candidate for a recombinant vaccine vehicle.
R G, Barletta +6 more
openaire +2 more sources
Development of BCG As a Recombinant Vaccine Vehicle
1990The bacille Calmette-Guerin (BCG) was developed by Dr A. Calmette and his associate Dr. C. Guerin at the Pasteur Institute in the early years of this century as a vaccine against tuberculosis. Despite enormous efforts by large numbers of experimental microbiologists of the time, the general methods for attenuating viruses and developing vaccines ...
W R, Jacobs +3 more
openaire +2 more sources